UBS Maintains a 'Neutral' on PharMerica (PMC); Trends Getting Worse
Tweet Send to a Friend
UBS maintains a 'Neutral' rating on PharMerica (NYSE: PMC), lowers PT from $16 to $13.
UBS analyst headlines: 1) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst headlines: 1) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
